These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30449480)

  • 1. Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Moris D; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Dec; 27(4):611-618. PubMed ID: 30449480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients.
    Tak WY; Ryoo BY; Lim HY; Kim DY; Okusaka T; Ikeda M; Hidaka H; Yeon JE; Mizukoshi E; Morimoto M; Lee MA; Yasui K; Kawaguchi Y; Heo J; Morita S; Kim TY; Furuse J; Katayama K; Aramaki T; Hara R; Kimura T; Nakamura O; Kudo M
    Invest New Drugs; 2018 Dec; 36(6):1072-1084. PubMed ID: 30198057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
    Bitzer M; Horger M; Giannini EG; Ganten TM; Wörns MA; Siveke JT; Dollinger MM; Gerken G; Scheulen ME; Wege H; Zagonel V; Cillo U; Trevisani F; Santoro A; Montesarchio V; Malek NP; Holzapfel J; Herz T; Ammendola AS; Pegoraro S; Hauns B; Mais A; Lauer UM; Henning SW; Hentsch B
    J Hepatol; 2016 Aug; 65(2):280-8. PubMed ID: 26952006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma.
    Streubel G; Schrepfer S; Kallus H; Parnitzke U; Wulff T; Hermann F; Borgmann M; Hamm S
    Sci Rep; 2021 May; 11(1):9587. PubMed ID: 33953226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.
    Zhang JX; Li DQ; He AR; Motwani M; Vasiliou V; Eswaran J; Mishra L; Kumar R
    Hepatology; 2012 Jun; 55(6):1840-51. PubMed ID: 22223166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of mPTP-dependent mitochondrial apoptosis pathway by a novel pan HDAC inhibitor resminostat in hepatocellular carcinoma cells.
    Fu M; Shi W; Li Z; Liu H
    Biochem Biophys Res Commun; 2016 Sep; 477(4):527-533. PubMed ID: 27144317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.
    Chang Y; Lee YB; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH
    BMC Cancer; 2020 Oct; 20(1):1001. PubMed ID: 33059615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platycodin D reverses histone deacetylase inhibitor resistance in hepatocellular carcinoma cells by repressing ERK1/2-mediated cofilin-1 phosphorylation.
    Hsu WC; Ramesh S; Shibu MA; Chen MC; Wang TF; Day CH; Chen RJ; Padma VV; Li CC; Tseng YC; Huang CY
    Phytomedicine; 2021 Feb; 82():153442. PubMed ID: 33412494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics and histone deacetylase inhibitors.
    Goey AK; Sissung TM; Peer CJ; Figg WD
    Pharmacogenomics; 2016 Nov; 17(16):1807-1815. PubMed ID: 27767376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.
    Gao JJ; Shi ZY; Xia JF; Inagaki Y; Tang W
    World J Gastroenterol; 2015 Nov; 21(42):12059-70. PubMed ID: 26576091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets.
    Neureiter D; Stintzing S; Kiesslich T; Ocker M
    World J Gastroenterol; 2019 Jul; 25(25):3136-3150. PubMed ID: 31333307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma.
    Spartalis E; Athanasiadis DI; Chrysikos D; Spartalis M; Boutzios G; Schizas D; Garmpis N; Damaskos C; Paschou SA; Ioannidis A; Tsourouflis G; Dimitroulis D; Nikiteas NI
    Anticancer Res; 2019 Mar; 39(3):1119-1127. PubMed ID: 30842140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer.
    Zhao J; Gray SG; Greene CM; Lawless MW
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):247-256. PubMed ID: 30791763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives.
    Zhu AX
    Semin Oncol; 2012 Aug; 39(4):493-502. PubMed ID: 22846866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
    J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.
    Freese K; Seitz T; Dietrich P; Lee SML; Thasler WE; Bosserhoff A; Hellerbrand C
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
    Gnoni A; Santini D; Scartozzi M; Russo A; Licchetta A; Palmieri V; Lupo L; Faloppi L; Palasciano G; Memeo V; Angarano G; Brunetti O; Guarini A; Pisconti S; Lorusso V; Silvestris N
    Expert Opin Ther Targets; 2015; 19(12):1623-35. PubMed ID: 26212068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone Deacetylase Inhibitors as Anticancer Drugs.
    Eckschlager T; Plch J; Stiborova M; Hrabeta J
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation of cofilin-1 by ERK confers HDAC inhibitor resistance in hepatocellular carcinoma cells via decreased ROS-mediated mitochondria injury.
    Liao PH; Hsu HH; Chen TS; Chen MC; Day CH; Tu CC; Lin YM; Tsai FJ; Kuo WW; Huang CY
    Oncogene; 2017 Apr; 36(14):1978-1990. PubMed ID: 27748761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.